Pfizer stock has experienced downward pressure and multi-period declines due to a steep post-pandemic drop-off in sales and demand for its COVID-19 vaccine and antiviral treatments. Additionally, patent expirations on several of its top-selling legacy blockbusters, expensive corporate acquisitions that increased debt levels, and mixed results or delays in select clinical pipelines have weighed on investor sentiment and long-term earnings growth expectations across the pharmaceutical giant.